BTK and B-cell non-Hodgkin lymphoma: One of the very important reasons is that he emergence of rituximab has improved the long-term prognosis of all patients with mature B-cell lymphoma.[18] Moreover, BTK inhibitors and CAR T-cell therapy also changed the clinical outcome of lymphoma cases.[19]